Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies

NCT00005811 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00005811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2000
Completion date
February 28, 2009
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related diffuse large cell lymphoma, aids-related diffuse mixed cell lymphoma, aids-related diffuse small cleaved cell lymphoma, aids-related immunoblastic large cell lymphoma, aids-related lymphoblastic lymphoma, aids-related peripheral/systemic lymphoma, aids-related primary cns lymphoma, aids-related small noncleaved cell lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, hiv-associated hodgkin lymphoma, leptomeningeal metastases, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood medulloblastoma, recurrent childhood small noncleaved cell lymphoma, recurrent/refractory childhood hodgkin lymphoma, unspecified childhood solid tumor, protocol specific